Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned an average rating of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $41.10.

GMAB has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a research note on Wednesday, January 28th. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a report on Tuesday. They issued a “buy” rating and a $41.50 price target on the stock. Morgan Stanley began coverage on Genmab A/S in a report on Monday. They set an “equal weight” rating and a $34.00 price objective for the company. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, Truist Financial reiterated a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company initiated a targeted share buy‑back to satisfy Restricted Stock Unit obligations (repurchase of up to 342,130 shares, max ~725 million DKK), which reduces float and signals capital allocation support for the stock. Genmab Announces Initiation of Share Buy-Back Program
• Positive Sentiment: Q4 results modestly beat EPS expectations: reported $0.47 EPS vs. $0.46 consensus, with revenue roughly in line at ~$1.06B and strong margins — a near-term fundamental positive. Q4 Slide Deck
• Positive Sentiment: Jefferies initiated coverage with a Buy and $41.50 target, representing meaningful upside vs. the current level — this can attract buyers and support sentiment. Benzinga
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the SEC — increases disclosure and transparency but is unlikely to move the stock materially on its own. Genmab Publishes 2025 Annual Report Genmab Files Annual Report (20-F)
• Neutral Sentiment: Morgan Stanley initiated coverage with an Equal Weight and $34 target — a mixed signal (coverage brings attention; Equal Weight is not a buy). Benzinga
• Neutral Sentiment: Investor materials and earnings‑call presentation posted (Seeking Alpha / slide deck) for deeper review of 2025 results and 2026 outlook. Useful for due diligence but not a headline mover. Earnings Presentation
• Neutral Sentiment: Short‑interest data reported appears anomalous (shows zero shares), so it offers no actionable signal to traders today.
• Negative Sentiment: Genmab updated FY‑2026 guidance but the published figures appear garbled/ inconsistent (revenue cited as “4.1–4.4 billionillion” vs. a cited consensus of “18.2 billionillion”). The unclear/likely erroneous guidance disclosure has likely increased investor uncertainty and could pressure the stock until clarified.

Genmab A/S Trading Down 0.1%

GMAB opened at $30.00 on Wednesday. The stock’s fifty day simple moving average is $32.30 and its 200 day simple moving average is $29.88. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $35.43. The stock has a market cap of $19.27 billion, a PE ratio of 12.77, a price-to-earnings-growth ratio of 17.63 and a beta of 0.90.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC grew its stake in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares in the last quarter. Yousif Capital Management LLC raised its stake in Genmab A/S by 7.8% in the 2nd quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock worth $226,000 after purchasing an additional 790 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Genmab A/S by 200.8% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,809 shares of the company’s stock valued at $120,000 after purchasing an additional 3,878 shares during the period. Oppenheimer Asset Management Inc. boosted its holdings in Genmab A/S by 2.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 254,551 shares of the company’s stock valued at $5,259,000 after purchasing an additional 5,083 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in shares of Genmab A/S by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 749,603 shares of the company’s stock worth $15,487,000 after purchasing an additional 13,277 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.